ClinicalTrials.gg
Active, not recruitingNCT06751264Updated Aug 3, 2026

Evaluation of the Efficacy and Safety of Microwave Ablation of Uterine Adenomyosis Under Improved Ultrasound Guidance

An interventional study of Peritoneal combined with intrauterine water isolation and Peritoneal water isolation in Adenomyosis of Uterus, sponsored by Peking University Aerospace Center Hospital. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Peking University Aerospace Center Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

This study aims to compare the safety and efficacy of segmental power adjustment combined with uterine cavity hydro-isolation in microwave ablation of adenomyosis

02

Conditions studied

  • Adenomyosis of Uterus

Browse trials for

03

In context

Adenomyosis

142 studies on the registry are indexed under Adenomyosis; 54 are open to participants now.

This study's planned enrollment of 137 is above the median of 100 across 78 interventional studies indexed under Adenomyosis.

Browse Adenomyosis studies →

Lead sponsor

Peking University Aerospace Center Hospital is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. UFs or AM diagnosed by pathology and ultrasound;
  2. Relevant symptoms such asabnormal uterine bleeding, secondary anemia, progressive dysmenorrhea and enlargement of the uterus;
  3. Voluntarily undergo MWA;
  4. a confirmed available safe transabdominal puncture path;

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or ;
  2. Severe and uncorrectable coagulation disorders;
  3. Severe cardiac, liver, and renal dysfunction;
  4. Anesthesia allergy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
137 participants (estimated)

Study arms

  • Experimental
    Peritoneal water isolation

    Peritoneal water isolation

    Procedure: Peritoneal water isolation

  • Experimental
    Peritoneal combined with intrauterine water isolation

    Peritoneal combined with intrauterine water isolation

    Procedure: Peritoneal combined with intrauterine water isolation

Interventions

  • ProcedurePeritoneal combined with intrauterine water isolation

    On the basis of the conventional peritoneal water isolation group, the improved technology group added additional intrauterine water isolation, and continued to inject ice saline to separate the endometrium on both sides.

  • ProcedurePeritoneal water isolation

    Transabdominal injection of saline into the abdominal cavity to achieve complete separation of the uterus from the surrounding organs and structures

06

What researchers measure

Primary outcomes

  1. The rates of endometrial injury

    Observe the differences in the rates of endometrial injury between two groups

    Time frame: From enrollment to the end of treatment at 3 months

Secondary outcomes

  1. The reduction rate of adenomyosis volume

    Observe the reduction rate of adenomyosis volume between two groups

    Time frame: From enrollment to the end of treatment at 1 year

  2. complication

    The complication rate between the two groups was compared

    Time frame: From enrollment to the end of treatment at 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06751264
Lead sponsor
Peking University Aerospace Center Hospital
Responsible party
Liang Lei (Peking University Aerospace Centre Hospital, Peking University Aerospace Center Hospital) — Principal investigator
First posted
Dec 27, 2024
Start date
Jan 20, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion